Navigation Links
Tunitas Therapeutics Awarded Phase II SBIR Grant to Advance Asthma Program
Date:6/4/2013

SAN FRANCISCO, June 4, 2013 /PRNewswire/ -- Tunitas Therapeutics, Inc., a private company discovering and developing novel human fusion proteins for the treatment of asthma and other allergic diseases, has been awarded a Small Business Innovation Research (SBIR) Phase II grant from the National Institute of Allergy and Infectious Disease (NIAID). The three-year, $3 million grant is aimed at advancing Tunitas' first clinical candidate, a member of the GE2 family, into preclinical development. Specifically the grant will support non-human primate efficacy studies, mechanism of action experiments, and discovery of a next-generation molecule. This grant brings Tunitas' NIH-led grant funding to nearly $10 million.

"This SBIR grant is an important step forward in the development of the Tunitas allergy platform," said Nolan Sigal , President and Chief Executive Officer of Tunitas. "Starting with the ground-breaking work of Dr. Andrew Saxon , Tunitas' co-founder and Emeritus Professor at the UCLA-Geffen School of Medicine, we have successfully advanced the GE2 Program to the point where we expect to begin human clinical trials in 2014."

Tunitas' lead compound GE2 is a fusion protein whose dual mechanism of action positions it to be a game-changing therapeutic for patients with moderate-to-severe asthma uncontrolled by conventional bronchodilators and inhaled corticosteroids, as well as for patients with severe, life-threatening food allergy. GE2 is a direct inhibitor of basophil and mast cell function, the primary cellular mediators of allergic disease, and it suppresses the production of allergic antibodies through its interaction with IgE-producing lymphocytes. GE2 is designed for long-term subcutaneous therapy to be given on an ongoing basis.

Asthma remains a significant unmet medical need in the United States and throughout the world. In the United States alone, this disease every year consumes $18 billion annually in healthcare costs, and, each day, causes 40,000 people to miss school or work, results in 1000 hospital admissions, and causes 11 deaths. Nearly 5 million asthma sufferers are under age 18. Asthma is the most common chronic childhood disease, affecting more than one child in 20.

About Tunitas Therapeutics
Tunitas Therapeutics, Inc. (San Francisco) is a privately held biopharmaceutical company that is developing novel and precisely targeted protein therapeutics with the potential to dramatically change the lives of allergy sufferers.  The company's therapeutic approach offers the potential for long-lasting treatments with safer, faster efficacy than conventional therapies, since they are capable of altering the natural course of such allergic diseases as food allergies, rhinitis and asthma. With close to $10 million raised to date in non-dilutive financing through peer-reviewed grants, Tunitas has successfully executed its capital efficient, semi-virtual business model. For more information on Tunitas Therapeutics, please visit the company's website at www.tunitastherapeutics.com.

Contact:

Nolan H. Sigal , M.D., Ph.D.
President & CEO
Tunitas Therapeutics, Inc.
(650) 887-4747
nsigal@tunitastherapeutics.com

Joan Kureczka
Kureczka/Martin Associates
(415) 821 2413
Joan@kureczka-martin.com


'/>"/>
SOURCE Tunitas Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Prime Therapeutics appoints Scott Fries as senior vice president of government programs
2. Sorrento Therapeutics to Present at the Jefferies 2013 Global Healthcare Conference in New York City
3. Nektar Therapeutics President and CEO, Howard W. Robin, To Present at the Jefferies 2013 Global Healthcare Conference in New York City
4. Orexigen Therapeutics to Present at the Jefferies 2013 Global Healthcare Conference
5. Protagonist Therapeutics Names David Liu Chief Scientific Officer
6. Echo Therapeutics to Present at the Jefferies Global Healthcare Conference
7. Alzheimer Market: Drugs, Therapeutics & Diagnostics Research Reports
8. Halozyme Therapeutics Names David A. Ramsay Chief Financial Officer
9. Inhibikase Therapeutics to present at Industry Conference on Drug-Induced Progressive Multifocal Leukoencephalopathy (PML)
10. Advanced Prenatal Therapeutics - Using Targeted Apheresis to Treat Preeclampsia
11. The Leukemia & Lymphoma Society, Valor Biotherapeutics and ImmunGene Create Partnership to Advance Novel Therapy for Non-Hodgkin Lymphoma Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2016)... , May 27, 2016 ... the Dario™ Diabetes Management Tool, today announced that the Company,s ... the Marcum MicroCap Conference being held June 1-2 in ... Invitational, being held June 7-9 in Los Angeles, ... will discuss recent corporate and operational milestones, including the U.S. ...
(Date:5/27/2016)... May 27, 2016 ... company focused on late-stage drug development, today announced ... of pivotal batches required for registration of ... (FDA). This follows Kitov,s announcement in ... successfully met its primary efficacy endpoint. ...
(Date:5/26/2016)... ALBANY, New York , May 26, 2016 ... Transparency Market Research "Medical Waste Management Market - U.S. Industry ... the medical waste management market in the U.S. was valued ... expand at a CAGR of 3.4% from 2015 to 2023 ... report provides exhaustive analysis of current and emerging needle free ...
Breaking Medicine Technology:
(Date:5/29/2016)... ... May 29, 2016 , ... Whole Health Supply is ... new KlipPro KP-240L clipper is available to the public. This is an unusual clipper ... wider than the average clipper. , Everything about this product is concentrated on ease ...
(Date:5/28/2016)... Aliso Viejo, California (PRWEB) , ... May 28, 2016 , ... ... just need to drag and drop a preset onto their media," said Christina Austin ... from Pixel Film Studios, editors can quickly and easily add stylish color grades to ...
(Date:5/28/2016)... ... May 28, 2016 , ... In a part of the city where’s it’s easy to spot ... Kelowna restaurants is hoping to attract diners with a taste for real food. ... opened the doors to Cornerstone Grill, an urban casual restaurant focusing on dishes made by ...
(Date:5/27/2016)... ... 2016 , ... Two director-level employees of Horizon Blue Cross Blue Shield of ... 2016 honorees. The award recognizes businesswomen who excel in their fields and who ... the MLTSS (Managed Long-Term Services and Supports) Program at Horizon NJ Health and Theresa ...
(Date:5/27/2016)... ... ... With over 60 percent of acute stroke survivors being left unable to ... in the rehabilitation process has steadily increased. Ekso Bionics had been working to help ... stroke. , Ekso Bionics has now received clearance from the U.S. Food and Drug ...
Breaking Medicine News(10 mins):